<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-74333</identifier>
<setSpec>1130-0108</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Oscillations in serum ferritin associated with antiviral therapy in chronic hepatitis C</dc:title>
<dc:description xml:lang="en">Background: hyperferritinemia is often found in patients with chronic hepatitis C (CHC) and is predictive of poorer response to antiviral therapy. Objective: to investigate changes in ferritinemia during and after antiviral therapy. Patients and methods: serum ferritin levels were measured in 262 CHC patients (163 males, mean age 48.5 years ± 10.1) before and during antiviral therapy, and six months post-treatment in all 154 patients whit undetectable serum HCV-RNA after therapy completion. Results: baseline serum ferritin was higher in patients with primary therapeutic failure than in those reaching sustained viral response (330 ± 291 ng/mL vs. 211 ± 192 ng/mL, p = 0.002). Serum ferritin transiently increased during therapy from baseline (257 ± 242 ng/mL vs. 875 ± 630 ng/mL, p &lt; 0.001). Six months after finishing therapy, serum ferritin decreased under baseline values both in sustained responders (117 ± 102 ng/mL vs. 211± 192 ng/mL, p &lt; 0.001) and, to a lesser extent, in relapsers (217 ± 174 ng/mL vs. 257 ± 221 ng/mL, p = 0.047). Conclusions: baseline serum ferritin may predict response to antiviral treatment in chronic hepatitis C. Combined antiviral therapy induces a marked increase in serum ferritin that falls below baseline values after sustained viral response, suggesting that the cause of hyperferritinemia in many patients is HCV infection itself rather than iron overload(AU)</dc:description>
<dc:creator>Ladero, J. M</dc:creator>
<dc:creator>Ortega, L</dc:creator>
<dc:creator>Agreda, M</dc:creator>
<dc:creator>Cuenca, F</dc:creator>
<dc:creator>López-Alonso, G</dc:creator>
<dc:creator>Suárez, A</dc:creator>
<dc:creator>Ropero, P</dc:creator>
<dc:creator>Díaz-Rubio, M</dc:creator>
<dc:creator>Devesa, M. J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Antecedentes: la hiperferritinemia es frecuente en los enfermoscon hepatitis crónica C (HCC) y reduce las probabilidades derespuesta al tratamiento antiviral.Objetivo: investigar las variaciones de la ferritina sérica durantey después del tratamiento y su relación con la respuesta al mismo.Pacientes y métodos: la ferritina sérica se ha medido en262 enfermos con HCC (163 hombres, edad media 48,5 años ±10,1) antes y durante el tratamiento antiviral, y a los 6 meses definalizado en los 154 enfermos con viremia indetectable al finaldel tratamiento.Resultados: la ferritina sérica basal era más alta en enfermoscon fracaso terapéutico primario que en los que consiguieron respuestaviral sostenida (RVS) (330 ± 291 ng/ml vs. 211 ± 192ng/ml, p = 0,002). La ferritina sérica aumentó transitoriamentedurante el tratamiento (257 ± 242 ng/ml vs. 875 ± 630 ng/ml, p&lt; 0,001). La ferritina sérica descendió a valores inferiores a losbasales seis meses después de finalizado el tratamiento en los pacientescon RVS (117 ± 102 ng/ml vs. 211± 192 ng/ml, p &lt;0,001) y, en menor grado, en los que sufrieron recidiva viral (217± 174 ng/ml vs. 257 ± 221 ng/m, p = 0,047).Conclusiones: una ferritina sérica basal elevada se asocia conmayor riesgo de fracaso terapéutico en la HCC. El tratamientoantiviral induce un marcado incremento de la ferritina sérica quevuelve a valores por debajo de los basales en los enfermos que obtienenRVS. Esto sugiere que la causa de hiperferritinemia en lamayoría de los enfermos es la propia infección por VHC y no lasobrecarga de hierro(AU)</dc:description>
<dc:source>Rev Esp Enferm Dig;101(1): 31-40, ene. 2009. tab</dc:source>
<dc:identifier>ibc-74333</dc:identifier>
<dc:title xml:lang="es">Oscilaciones de la ferritina sérica asociadas al tratamiento antiviral en la hepatitis crónica por virus C</dc:title>
<dc:subject>^d33343^s22016</dc:subject>
<dc:subject>^d5402^s22073</dc:subject>
<dc:subject>^d32731</dc:subject>
<dc:subject>^d^s22073</dc:subject>
<dc:subject>^d33343^s22067</dc:subject>
<dc:subject>^d922^s22073</dc:subject>
<dc:subject>^d30351^s32386</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d15175^s22066</dc:subject>
<dc:subject>^d15175^s22045</dc:subject>
<dc:subject>^d29469^s22073</dc:subject>
<dc:subject>^d12663^s22073</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d32730</dc:subject>
<dc:type>article</dc:type>
<dc:date>200901</dc:date>
</metadata>
</record>
</ibecs-document>
